Linagliptin is an Effective Therapeutic for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)

被引：0
|
作者：
Klein, Thomas
Mark, Michael
机构：
来源：
DIABETES | 2012年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1035-P
引用
收藏
页码：A265 / A266
页数：2
相关论文
共 50 条
  • [21] Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Eslami, Layli
    Merat, Shahin
    Malekzadeh, Reza
    Nasseri-Moghaddam, Siavosh
    Aramin, Hermineh
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [22] Liver stiffness measurement using transient elastography in patients with non-alcoholic fatty liver (NAFLD) and non-alcoholic steatohepatitis (NASH)
    Miette, Veronique
    Fournier, Celine
    Adara, Linda
    Sandrin, Laurent
    2007 IEEE ULTRASONICS SYMPOSIUM PROCEEDINGS, VOLS 1-6, 2007, : 1333 - 1336
  • [23] Predictive Value of ALT for Diagnosing Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
    Verma, Siddharth
    Sharma, Prashant
    Hart, John
    Mohanty, Smruti R.
    GASTROENTEROLOGY, 2012, 142 (05) : S1019 - S1020
  • [24] HLA Class II Alleles Are Strongly Associated with Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Fibrosis
    Karrar, Azza
    Li, Zheng
    Moosvi, Ali M.
    Hariharan, Siddharth
    Fang, Yun
    Stepanova, Maria
    Goodman, Zachary D.
    Younossi, Zobair
    HEPATOLOGY, 2014, 60 : 601A - 602A
  • [25] Components of Metabolic Syndrome and the Rising Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in the United States
    Stepanova, Maria
    Afendy, Mariam
    Vernon, Gregory C.
    Nader, Fatema
    Younossi, Zobair M.
    GASTROENTEROLOGY, 2011, 140 (05) : S988 - S988
  • [26] Independent Predictors of Non-alcoholic Steatohepatitis (NASH) and Advanced Fibrosis in a Large Cohort of Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
    Fang, Yun
    Rafiq, Nila
    Afendy, Mariam
    Younossi, Youssef
    Lam, Brian
    Goodman, Zachary
    Younossi, Zobair
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S120 - S120
  • [27] Melanocortins and Interleukins Contributing to Advanced Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in Patients With BMI ≥ 40
    Baranova, Ancha
    Jarrar, Mohammed
    Moazzez, Amir H.
    Elariny, Hazem
    Abawi, Massih
    Wang, Lei
    Afendy, Arian
    Stepanova, Maria
    Estep, J. M.
    Younossi, Zobair M.
    OBESITY, 2011, 19 : S87 - S87
  • [28] NASH (Non-Alcoholic Steatohepatitis): Fatty Liver or Fatal Liver Disease?
    Roeb, E.
    ZENTRALBLATT FUR CHIRURGIE, 2014, 139 (02): : 168 - 174
  • [29] Sex difference in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Tomiya, Tomoaki
    HEPATOLOGY RESEARCH, 2010, 40 (01) : 108 - 110
  • [30] CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Sila Cocciolillo
    Giustino Parruti
    Leonardo Marzio
    World Journal of Hepatology, 2014, (07) : 496 - 503
12345